These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24928346)

  • 21. Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata.
    Alatabani M; Ghobara Y; Alissa A
    Case Rep Dermatol; 2021; 13(1):36-41. PubMed ID: 33613232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy & recurrence rates of imiquimod cream 5% for treatment of anogenital warts.
    Diamantis ML; Bartlett BL; Tyring SK
    Skin Therapy Lett; 2009 Jun; 14(5):1-3, 5. PubMed ID: 19609471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.
    Syed TA; Ahmadpour OA; Ahmad SA; Ahmad SH
    J Dermatol; 1998 Jul; 25(7):429-33. PubMed ID: 9714974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
    Fife KH; Ferenczy A; Douglas JM; Brown DR; Smith M; Owens ML;
    Sex Transm Dis; 2001 Apr; 28(4):226-31. PubMed ID: 11318254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of the area of skin capable of being covered by the application of 250 mg of 5% imiquimod cream.
    Berman B; Ricotti CA; Cazzaniga A; Davis SC
    Dermatol Surg; 2004 May; 30(5):784-6. PubMed ID: 15099325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
    Edwards L; Ferenczy A; Eron L; Baker D; Owens ML; Fox TL; Hougham AJ; Schmitt KA
    Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.
    Hoyme UB; Hagedorn M; Schindler AE; Schneede P; Hopfenmüller W; Schorn K; Eul A
    Infect Dis Obstet Gynecol; 2002; 10(2):79-88. PubMed ID: 12530484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions.
    Carrasco D; vander Straten M; Tyring SK
    J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S212-6. PubMed ID: 12271280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
    Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
    J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitiligo or Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Condyloma Acuminatum: Not a Casual Event.
    Long FQ; Zhao LS; Qian YH
    Chin Med J (Engl); 2017 Feb; 130(4):503-504. PubMed ID: 28218231
    [No Abstract]   [Full Text] [Related]  

  • 31. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women.
    Garland SM; Waddell R; Mindel A; Denham IM; McCloskey JC
    Int J STD AIDS; 2006 Jul; 17(7):448-52. PubMed ID: 16820073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imiquimod: a review.
    Gupta AK; Browne M; Bluhm R
    J Cutan Med Surg; 2002; 6(6):554-60. PubMed ID: 12362256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of 5% imiquimod cream in external genital warts: a 6 month follow-up evaluation].
    Vexiau D; Decuypère L; Moyse D; Aractingi S
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):845-51. PubMed ID: 16327713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of genital warts with an immune-response modifier (imiquimod).
    Beutner KR; Spruance SL; Hougham AJ; Fox TL; Owens ML; Douglas JM
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):230-9. PubMed ID: 9486679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata.
    Yan J; Chen SL; Wang HN; Wu TX
    Dermatology; 2006; 213(3):218-23. PubMed ID: 17033171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genital Vitiligo-like Hypopigmentation After Treatment With 5% Imiquimod.
    García-Montero P; Repiso Jiménez JB; Fernández Morano MT; de Troya Martín M
    Actas Dermosifiliogr; 2017 May; 108(4):378-380. PubMed ID: 27912903
    [No Abstract]   [Full Text] [Related]  

  • 37. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts--results of an open-label, multicentre Phase IIIB trial.
    Garland SM; Sellors JW; Wikstrom A; Petersen CS; Aranda C; Aractingi S; Maw RD;
    Int J STD AIDS; 2001 Nov; 12(11):722-9. PubMed ID: 11589811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imiquimod in clinical practice.
    Edwards L
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S14-6. PubMed ID: 9842096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of extensive condyloma acuminata of the inguinal area and thigh with topical imiquimod cream.
    Weinberg JM; Stewart A; Stern JO
    Acta Derm Venereol; 2001; 81(1):76-7. PubMed ID: 11411935
    [No Abstract]   [Full Text] [Related]  

  • 40. Imiquimod is highly effective for extensive, hyperproliferative condyloma in children.
    Majewski S; Pniewski T; Malejczyk M; Jablonska S
    Pediatr Dermatol; 2003; 20(5):440-2. PubMed ID: 14521566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.